Gasporox: Best quarter yet - Redeye

Redeye comments on Gasporox Q1'23 report which beat expectations across the board. Gasporox is executing on the long-term opportunity, expanding its geographic reach and product portfolio. We make a slight negative revision to our Q2'23 esimate on the back of the strong Q1'23 report. We reiterate our base case of SEK25.

Länk till analysen i sin helhet: https://www.redeye.se/research/895701/gasporox-best-quarter-yet?utm_source=finwire&utm_medium=RSS